JUL 24, 2015 2:58 PM PDT

Radiotherapy-Resistant Tumors

WRITTEN BY: Ilene Schneider
By discovering how micro-RNAs, small regulatory molecules in cells, render prostate cancer resistant to radiotherapy, researchers at the University of York in the United Kingdom believe that they can develop more effective prostate cancer treatments. Such treatments would enable the use of lower doses of chemotherapy while being effective and potentially saving the lieves of thousands of men. Prostate cancer, the most commonly diagnosed form of male cancer in the UK, takes the lives of more than 11,000 men every year, according to an article in Drug Discovery News (http://www.dddmag.com/news/2015/07/scientists-discover-why-some-prostate-cancer-tumors-are-radiotherapy-resistant?et_cid=4692171&et_rid=45505806&type=cta).
University of York scientists try for a better way to treat prostate cancer.
According to the National Cancer Institute (NCI), prostate cancer is the most common nonskin cancer and the second leading cause of cancer-related death in men in the United States. NCI estimated that, in 2014, 233,000 men would be diagnosed with prostate cancer in the US, and nearly 29,500 men would succumb to the disease. Prostate cancer incidence rates in the United States began to increase dramatically in the late 1980s with the widespread use of the prostate-specific antigen (PSA) test to detect prostate cancer. During the 1990s both incidence and mortality rates for prostate cancer have declined (http://www.cancer.gov/research/progress/snapshots/prostate).

As published in European Urology and the British Journal of Cancer, scientists at the YCR Cancer Research Unit in the Department of Biology at York have established a direct connection between the micro-RNA molecules and radiotherapy resistance. Each cell has micro-RNAs that control the gene expression. They are involved in the organization of various tissues in the body, telling genes when and where to be active. According to the York scientists, micro-RNAs act as the switch that enables cells to react quickly to changes in their environment, such as a dose of chemotherapy.

According to previous research, all prostate cancers have at least four different cell types, including the cancer stem cells that resist most current treatments. When the York researchers looked at the micro-RNAs in each of the cell types individually, they discovered that some micro-RNAs acted in a positive manner, switching off genes which could make the stem cells susceptible to radiotherapy. Other micro-RNAs were not expressed in the resistant stem cells, enabling the expression of resistance genes. If the levels of these micro-RNAs in the clinic can be manipulated in the clinic, it could be possible to kill greater numbers of cancer stem cells, addressing the issue that 30 percent of prostate cancer patients have a recurrence of their tumors after radiotherapy.

As Professor Norman Maitland, of the YCR Cancer Research Unit, summarized, "Doctors don't know which patients are going to relapse - and the reason they relapse is probably because the radiotherapy is not focused on the stem cell; it is focused on the whole tumor. By exploiting this new knowledge, we can make radiotherapy more effective. It could extend the lifetime of these men. It could also allow a lower dose of radiotherapy to be used, and that's really what we are testing at the moment. This will be the bridge to transforming that into a treatment and making radiotherapy better."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
AUG 13, 2021
Drug Discovery & Development
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
AUG 13, 2021
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The stu ...
AUG 24, 2021
Clinical & Molecular DX
A New Chapter in Metastatic Breast Cancer Biomarkers
AUG 24, 2021
A New Chapter in Metastatic Breast Cancer Biomarkers
For patients diagnosed with metastatic breast cancer, it’s often not the primary tumor that has fatal consequences ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
NOV 11, 2021
Clinical & Molecular DX
Cancer Pathologist Burnout? AI to the Rescue.
NOV 11, 2021
Cancer Pathologist Burnout? AI to the Rescue.
Diagnosing cancer is hard work. The challenging demands of their caseloads see diagnostic pathologists in many clinical ...
NOV 17, 2021
Cancer
Turkey, Tryptophan, and Cancer
NOV 17, 2021
Turkey, Tryptophan, and Cancer
As many people start to plan their Thanksgiving dinners, there will inevitably be a lot of talk about the turkey.  ...
NOV 25, 2021
Cancer
Could an Anti-Cancer Drug Treat Diabetes?
NOV 25, 2021
Could an Anti-Cancer Drug Treat Diabetes?
Diabetes and cancer are two common diseases that share many similar risk factors. People with diabetes are also at& ...
Loading Comments...